DataLabs Announces Launch of Site Manager 2.0, an Advanced CT Management Portal Including Digital Signature Technology
DataLabs is the first vendor to implement electronic signatures out-of-the-box guaranteeing signer authenticity and data integrity.
PHILADELPHIA-June 19, 2006-DataLabs, an innovative developer of Internet-based software applications for clinical development, today announced the launch of Site Manager™ 2.0 at the 42nd Annual Drug Information Association (DIA) Meeting. Advanced clinical trial software, Site Manager 2.0 improves the site selection and activation processes as well as overall site satisfaction with easy to use, Web-based site management software. Site Manager 2.0 integrates CoSign®, Algorithmic Research's (ARX's) electronic signature solution, enabling users to sign documents with secure, regulatory compliant, electronic signatures that complete the migration to paperless processes, further streamlining clinical trial efficiency.
Site Manager 2.0 is a communication portal that extends electronic data capture, allowing sponsors, clinical research organizations (CROs), investigator sites and other trial participants to streamline data exchange and entry, document processing and data management. With Site Manager 2.0, sponsors or CROs can quickly identify and initiate investigator sites and then monitor and administer the site during the course of the trial. Built on Microsoft's SharePoint technology, Site Manager 2.0 meets CDISC ODM standards and complies with FDA 21 CFR Part 11.
DataLabs will be at booth #1829 at the DIA Annual Conference.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
